Zobrazeno 1 - 3
of 3
pro vyhledávání: ''
Publikováno v:
npj Breast Cancer, Vol 6, Iss 1, Pp 1-12 (2020)
NPJ Breast Cancer
NPJ Breast Cancer
Recurrence of estrogen receptor (ER)-positive breast tumors despite curative-intent adjuvant therapy is thought to be due to enrichment of tumor initiating cells (TIC) during endocrine therapy (ET). Recently, it was identified that by antagonizing th
Autor:
Lina Asmar, Frankie A. Holmes, Yunfei Wang, Cynthia Osborne, Deborah Lindquist, Joanne L. Blum, Devchand Paul, Joyce O'Shaughnessy, Jerome H. Goldschmidt, Svetislava J. Vukelja, Lewis C. Strauss, Kristi McIntyre, Ines J. Sanchez
Publikováno v:
npj Breast Cancer, Vol 5, Iss 1, Pp 1-7 (2019)
NPJ Breast Cancer
NPJ Breast Cancer
The non-receptor tyrosine kinase Src activation plays a role in the malignant progression of breast cancer, including development of endocrine therapy resistance and survival of bone metastases. This study investigated whether adding Src kinase inhib
Autor:
Bernard Rosner, Rulla M. Tamimi, Hannah Oh, Walter C. Willett, Stuart J. Schnitt, A. Heather Eliassen, Laura C. Collins, Laleh Montaser-Kouhsari, Andrew H. Beck, James L. Connolly
Publikováno v:
npj Breast Cancer, Vol 3, Iss 1, Pp 1-8 (2017)
NPJ Breast Cancer
NPJ Breast Cancer
Studies have suggested that hormone receptor and Ki67 expression in normal breast tissue are associated with subsequent breast cancer risk. We examined the associations of breast cancer risk factors with estrogen receptor (ER), progesterone receptor